日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial

回复:优化慢性淋巴细胞白血病临床试验中的对照组:BRUIN-CLL-321试验

Sharman, Jeff P; Liu, Bin; Wang, Denise Y; Leow, Ching Ching; Barr, Paul M

Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma

研究血浆ctDNA和外周T细胞受体库的早期动力学以预测头颈部鳞状细胞癌患者对PD-1抑制剂的治疗结果

Sanz-Garcia, Enrique; Soleimani, Shirin; Bruce, Jeff P; Pedersen, Stephanie; Tang, Marian; Avery, Lisa; Eagles, Jenna; Spreafico, Anna; Hansen, Aaron R; Eng, Lawson; Laliotis, George; Krainock, Michael; Liu, Minetta; Basra, Prabhjit; Yu, Celeste; Felicen, Sam; Ohashi, Pamela S; Bratman, Scott V; Pugh, Trevor J; Siu, Lillian L

Assessing Patient Discomfort in Smartphone-Based Teledentistry From the Perspective of Dental Professionals: Qualitative Interview Study

从牙科专业人员的角度评估基于智能手机的远程牙科诊疗中患者的不适感:一项定性访谈研究

Shenouda, Margaret; Huang, Boyen; Schultz, Emily C; Estai, Mohamed; Ranjitkar, Sarbin; Louie, Jeff P; Pungchanchaikul, Patimaporn

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

大型临床试验中患者报告结局(PRO)与临床医生报告的不良事件:POLARIX 3期研究结果

Thompson, Carrie; Trněný, Marek; Morschhauser, Franck; Salles, Gilles; Reagan, Patrick M; Hertzberg, Mark; Zhang, Huilai; Thieblemont, Catherine; Hu, Bei; Fonseca, Gustavo; Kim, Won Seog; Martelli, Maurizio; Mehta, Amitkumar; Singh, Avrita; Yan, Mark; Hirata, Jamie; Sugidono, Matthew; Lee, Calvin; Sharman, Jeff P; Mehta-Shah, Neha; Flowers, Christopher R; Tilly, Hervé; Chua, Neil; Casasnovas, René-Olivier; Miall, Fiona; Kim, Tae Min; Tsai, Xavier Cheng-Hong; Nasta, Sunita; Lee, Seung Tae; Friedberg, Jonathan W

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

在共价布鲁顿酪氨酸激酶抑制剂预处理的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中,Pirtobrutinib 与 Idelalisib/Rituximab 或 Bendamustine/Rituximab 的 III 期试验 (BRUIN CLL-321)

Sharman, Jeff P; Munir, Talha; Grosicki, Sebastian; Roeker, Lindsey E; Burke, John M; Chen, Christine I; Grzasko, Norbert; Follows, George; Mátrai, Zoltán; Sanna, Alessandro; Qiu, Lugui; Feng, Ru; Hua, Vu Minh; Jurczak, Wojciech; Ritgen, Matthias; Yi, Shuhua; Bosch, Francesc; Coombs, Catherine C; Bao, Katherine; Patel, Vishalkumar; Liu, Bin; Compte, Livia; Guntur, Ananya; Wang, Denise Y; Hill, Marisa; Leow, Ching Ching; Ghia, Paolo; Barr, Paul M

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

POLARIX 研究五年结果:比较 Pola-R-CHP 和 R-CHOP 方案治疗弥漫性大 B 细胞淋巴瘤患者的疗效

Morschhauser, Franck; Salles, Gilles; Sehn, Laurie H; Herrera, Alex F; Friedberg, Jonathan W; Trněný, Marek; Lenz, Georg; Sharman, Jeff P; Herbaux, Charles; Burke, John M; Matasar, Matthew; Collins, Graham P; Mehta-Shah, Neha; Oberic, Lucie; Chauchet, Adrien; Jurczak, Wojciech; Song, Yuqin; Pinto, Antonio; Rai, Shinya; Izutsu, Koji; Greil, Richard; Mykhalska, Larysa; Bergua-Burgués, Juan M; Cheung, Matthew C; Shin, Ho-Jin; Hapgood, Greg; Munhoz, Eduardo; Abrisqueta, Pau; Gau, Jyh-Pyng; Jiang, Yanwen; McCall, Bruce; Chohan, Saibah; Sugidono, Matthew; Yan, Mark; Batlevi, Connie Lee; Tilly, Hervé; Flowers, Christopher R

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

在ELEVATE-TN研究的6年随访结果中,阿卡替尼联合奥妥珠单抗治疗与化疗免疫疗法相比,可改善初治慢性淋巴细胞白血病患者的生存期。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Patel, Krish; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Hughes, Marie; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Follows, George; Walker, Patricia; Ghia, Paolo; Janssens, Ann; Byrd, John C; Ferrant, Emmanuelle; Ferrajoli, Alessandra; Wierda, William G; Wachira, Catherine Wangui; Suterwala, Batul T; Miranda, Paulo; Munugalavadla, Veerendra; Wun, Chuan-Chuan; Woyach, Jennifer A

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

更正:ELEVATE-TN 研究 4 年随访结果显示,在初治慢性淋巴细胞白血病患者中,阿卡替尼联合或不联合奥妥珠单抗与奥妥珠单抗联合苯丁酸氮芥的疗效和安全性。

Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Pagel, John M; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Coutre, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Paolo; Janssens, Ann; Cymbalista, Florence; Woyach, Jennifer A; Ferrant, Emmanuelle; Wierda, William G; Munugalavadla, Veerendra; Yu, Ting; Wang, Min Hui; Byrd, John C

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality.

通过合成剂量致死性鉴定 PLK1 过表达癌症的可靶向脆弱性

Cunningham Chelsea E, Vizeacoumar Frederick S, Zhang Yue, Kyrylenko Liliia, Both Simon, Maranda Vincent, Dong He, Price Jared D W, Gao Peng, Wagner Konrad, Wu Yingwen, Lazell-Wright Mary, Ganapathysamy Ashtalakshmi, Hari Rithik, Bhanumathy Kalpana K, Denomy Connor, Saxena Anjali, Vizeacoumar Jeff P, Morales Alain Morejon, Khan Faizaan, Mosley Shayla, Chen Angie, Katrii Tetiana, Zoller Ben G E, Rajamanickam Karthic, Walke Prachi, Gong Lihui, Patel Hardikkumar, Elhasasna Hussain, Dahiya Renuka, Abuhussein Omar, Dmitriev Anton, Freywald Tanya, Munhoz Erika Prando, Ruppin Eytan, Lee Joo Sang, Rox Katharina, Koebel Martin, Hopkins Laura, Lee Cheng Han, Yadav Sunil, Gasparoni Gilles, Walter Jörn, Krishnan Anand, Datla Raju, Toosi Behzad, Baker Kristi, Meens Jalna, Cescon David W, Ailles Laurie, Leary Scot C, Wu Yuliang, Empting Martin, Kiemer Alexandra K, Freywald Andrew, Vizeacoumar Franco J

The dichotomous behavior of allylsilanes in the additions to platinum α,β-unsaturated carbenes

烯丙基硅烷在与铂α,β-不饱和卡宾加成反应中的二元行为

Costello, Jeff P; Garber, Jacob P; Huynh, Khoi Q; Ferreira, Eric M